Login to Your Account

First of the glimins, Poxel diabetes drug hits phase IIb endpoint

By Cormac Sheridan
Staff Writer

Thursday, December 18, 2014

DUBLIN – Top-line data indicate the optimal dose of Poxel SA's first-in-class diabetes drug imeglimin hit the primary endpoint of a phase IIb dose-finding study in 382 patients with type 2 diabetes, with an average reduction in glycosylated hemoglobin (HbA1c) levels of 0.63 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription